Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 277

Similar articles for PubMed (Select 12612238)

1.

Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.

Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML.

Pediatrics. 2003 Mar;111(3):573-8.

PMID:
12612238
2.

Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.

Andiran N, Alikasifoglu A, Gonc N, Ozon A, Kandemir N, Yordam N.

J Pediatr Endocrinol Metab. 2008 Jan;21(1):63-72.

PMID:
18404974
3.

Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.

Land C, Rauch F, Travers R, Glorieux FH.

Bone. 2007 Mar;40(3):638-44. Epub 2006 Nov 28.

PMID:
17127117
4.

Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.

Poyrazoglu S, Gunoz H, Darendeliler F, Bas F, Tutunculer F, Eryilmaz SK, Bundak R, Saka N.

J Pediatr Orthop. 2008 Jun;28(4):483-7. doi: 10.1097/BPO.0b013e318173a923.

PMID:
18520289
5.

Bone densitometry in pediatric patients treated with pamidronate.

Grissom LE, Kecskemethy HH, Bachrach SJ, McKay C, Harcke HT.

Pediatr Radiol. 2005 May;35(5):511-7. Epub 2005 Jan 18.

PMID:
15655696
6.

Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.

DiMeglio LA, Ford L, McClintock C, Peacock M.

Bone. 2004 Nov;35(5):1038-45.

PMID:
15542028
7.

Cyclic pamidronate therapy in children with osteogenesis imperfecta.

Salehpour S, Tavakkoli S.

J Pediatr Endocrinol Metab. 2010 Jan-Feb;23(1-2):73-80.

PMID:
20432809
8.

Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.

DiMeglio LA, Peacock M.

J Bone Miner Res. 2006 Jan;21(1):132-40. Epub 2005 Oct 17.

PMID:
16355282
9.

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.

Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC.

J Bone Miner Res. 2005 Jun;20(6):977-86. Epub 2005 Jan 18.

PMID:
15883638
10.

Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study.

Forin V, Arabi A, Guigonis V, Filipe G, Bensman A, Roux C.

Joint Bone Spine. 2005 Jul;72(4):313-8. Epub 2004 Dec 15.

PMID:
16038843
11.

Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.

Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH.

Bone. 2006 Oct;39(4):901-6. Epub 2006 May 26.

PMID:
16730480
12.

Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution.

Alharbi M, Pinto G, Finidori G, Souberbielle JC, Guillou F, Gaubicher S, Le Merrer M, Polak M.

Horm Res. 2009 Jan;71(1):38-44. doi: 10.1159/000173740. Epub 2008 Nov 27.

PMID:
19039235
13.

Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome.

Munns CF, Rauch F, Travers R, Glorieux FH.

J Bone Miner Res. 2005 Jul;20(7):1235-43. Epub 2005 Feb 21.

PMID:
15940378
14.
15.

A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.

Dimeglio LA, Ford L, McClintock C, Peacock M.

J Pediatr Endocrinol Metab. 2005 Jan;18(1):43-53.

PMID:
15679068
17.

Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.

Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tatò L, Viapiana O, Adami S.

J Bone Miner Res. 2005 May;20(5):758-63. Epub 2004 Dec 20.

PMID:
15824848
18.

Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.

Vallo A, Rodriguez-Leyva F, Rodríguez Soriano J.

Acta Paediatr. 2006 Mar;95(3):332-9.

PMID:
16497645
20.

The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.

Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH.

Bone. 2006 Jan;38(1):13-20. Epub 2005 Sep 12.

PMID:
16162424
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk